Navigation Links
Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
Date:6/10/2009

SEATTLE, June 10 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that a summary of the pixantrone Phase III clinical data that were presented at American Society of Clinical Oncology (ASCO) 2009 Annual Meeting on June 1, 2009 is now available at Clinical Care Options website http://www.clinicaloptions.com. Clinical Care Options is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs. The ASCO summaries are "quick read" reviews of key oral sessions and poster presentations, which are handpicked by leading experts in oncology and hematology for the Clinical Care Options website.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

    Media Contact:

    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: deramian@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:

    Ed Bell
    T: 206.282.7100
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors

    Medical Information Contact:

    T: 800.715.0944
    E: info@askarm.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
4. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
5. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
6. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
7. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
8. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
9. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
10. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
11. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 17, 2017 Research and Markets has announced the ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , and Rest of World. Annual estimates and ... historic analysis is provided for these markets. Market data and analytics are ...
(Date:2/17/2017)... ST. LOUIS , Feb. 17, 2017   ... hospitals, has announced a new partnership with Engage ... the United States . FormFast will serve ... part of Engage,s implementations with MEDITECH .  ... that provides essential functionality to complement and enhance the ...
(Date:2/17/2017)... 2017  Noble Capital Markets announced today that it ... EPIX ). The report was issued by ... PhD. ESSA Pharmaceuticals is a clinical stage ... (CRPC). Its lead compound EPI-506, is a small molecule ... the androgen receptor, thereby has potential to overcome some ...
Breaking Medicine Technology:
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, Joette ... the Pet Life Radio network. The episode, which was posted this week, features ... what factors led to Park Cities Pet Sitter’s being awarded the 2017 National Association ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... kept pace. Enovate Medical has introduced an innovative workstation designed to reduce nursing ... nurses, the Encore Mobile EHR Workstation offers a lightweight, highly mobile, multi-functional alternative ...
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
(Date:2/17/2017)... Sulphur Springs, Texas (PRWEB) , ... February 17, ... ... Electronic Signature 8.0 at the HIMSS17 Conference & Exhibition in Orlando, Fla., February ... the latest version of the most widely used electronic patient signatures solution ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... their Chief Executive Officer, George Rogers, was named to Staffing Industry Analysts' 2017 ... Staffing 100 honors those who have made notable contributions to the staffing industry ...
Breaking Medicine News(10 mins):